


**CHOKSI LABORATORIES LIMITED**

**Statement of Unaudited Financial Results for the Quarter & 3 Month Ended on 30th June'2021**

Sl. No.	PARTICULARS	(Rs. In Lacs)			
		Quarter ended			Year ended
		3 Month ended	Preceding 3 Month ended	Corresponding 3 months ended in the previous year	Year to Date figures for the current period
		30.06.2021	31.03.2021	30.06.2020	31.03.2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	<b>Revenue from Operations</b>	532.84	734.48	480.50	2568.80
II	Other Operating Revenue	9.20	2.57	20.63	48.82
III	<b>Total Revenue from Operations (Net) (I+II)</b>	<b>542.04</b>	<b>737.05</b>	<b>501.13</b>	<b>2617.62</b>
IV	<b>Expenses</b>				
	(a) Cost of materials consumed	51.00	64.83	60.14	256.53
	(b) Employee benefits expenses	273.06	316.34	200.44	1150.08
	(c) Finance Cost	86.49	84.77	58.45	281.83
	(d) Depreciation and amortisation expenses	135.68	125.67	112.16	460.30
	(e) Laboratory Maintenance Expenses	53.42	66.83	42.69	264.53
	(f) Power & Fuel Charges	17.56	12.09	16.51	65.69
	(g) Other expenses	108.33	109.33	88.94	419.48
	<b>Total expenses</b>	<b>725.54</b>	<b>779.86</b>	<b>579.33</b>	<b>2898.44</b>
V	<b>Profit / (Loss) from operations before exceptional items and tax (III-IV)</b>	<b>(183.50)</b>	<b>(42.81)</b>	<b>(78.20)</b>	<b>(280.82)</b>
VI	Exceptional items	-	-	-	-
VII	<b>Profit / (Loss) before tax (V-VI)</b>	<b>(183.50)</b>	<b>(42.81)</b>	<b>(78.20)</b>	<b>(280.82)</b>
VIII	<b>Tax Expenses</b>				
	(a) Current Tax	-	-	-	-
	(b) Deferred Tax	(29.94)	(3.81)	(1.85)	(20.05)
IX	<b>Net Profit / (Loss) for the period from continuing operations (VII-VIII)</b>	<b>(153.56)</b>	<b>(39.00)</b>	<b>(76.35)</b>	<b>(260.77)</b>
X	<b>Other Comprehensive Income</b>				
	(a) (i) Items that will not be reclassified to profit & loss	4.50	10.54	2.50	18.04
	loss	(1.17)	(2.74)	(0.65)	(4.69)
	(b) (i) Items that will be re-classified to profit & loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit & loss	-	-	-	-
XI	<b>Total Comprehensive Income (IX+X)</b>	<b>(150.23)</b>	<b>(31.20)</b>	<b>(74.50)</b>	<b>(247.42)</b>
XII	<b>Details of equity share capital</b>				
	(a) Paid-up equity share capital	696.52	696.52	696.52	696.52
	(b) Face value of equity share capital (in Rs)	10.00	10.00	10.00	10.00
XIII	<b>Earnings per equity share (for continuing operations)</b>				
	(a) Basic	(2.20)	(0.56)	(1.10)	(3.74)
	(b) Diluted	(2.20)	(0.56)	(1.10)	(3.74)
XVI	<b>Earnings per equity share for (Dis-continuing operations)</b>				
	(a) Basic	-	-	-	-
	(b) Diluted	-	-	-	-
XV	<b>Earnings per equity share (for Dis-continued and continuing operations)</b>				
	(a) Basic	(2.20)	(0.56)	(1.10)	(3.74)
	(b) Diluted	(2.20)	(0.56)	(1.10)	(3.74)

Cont...

For Choksi Laboratories Ltd.



Director

**Corporate Office & Central Laboratory :**

Survey No. 9/1., Balaji Tulsiyana Industrial Park,  
Kumedi, Off. M.R. 10 Toll Naka, Indore – 452010, M.P. (India)

Tel. +91 731 3501112 (60 Lines)

Email : indore@choksilab.com

Website : www.choksilab.com

**Notes to the results :**

- 1 These results have been prepared in accordance with the Indian Accounting Standards (Ind AS) notified under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules 2015 as amended.
- 2 "Other Income" for the quarter ended 30 June 2021 includes :-  
Interest Income at fair value as per IND AS Rs. 15232.00, Interest on IT refund Rs. 6,41,718.00 and Interest received Rs. 2,63,309.00
- 3 The Company continues to consider the impact of COVID-19 pandemic in assessing the recoverability of receivables, and intangible assets. For this purpose, the Company considered internal and external sources of information up to the date of approval of these financial results. The Company based on its judgements, estimates and assumptions including sensitivity analysis expects to fully recover the canying amount of receivables, intangible assets, and other assets. The Company will continue to closely monitor any material changes to future economic conditions.
- 4 The figures of the quarter ended 31 March 2021 are the balancing number between audited figures in respect of the full financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year, which are subject to limited review.
- 5 The above Financial Results for the quarter ended on 30th June 2021 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Friday, 13th August 2021.
- 6 The results for the quarter ended 30th June 2021 were subjected to "Limited Review" by the auditor and their report contains no qualification.
- 7 Depreciation on fixed assets is provided on straight line method as per the estimated remaining useful life of assets.
- 8 The Company has identified "Analysis and Testing" as the single operating segment for the continued operations in the financial statements as per Ind AS 108 "Operating Segments.
- 9 The above financial results have been prepared as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India.
- 10 Earnings per share amount shown in Rupees.
- 11 For any queries e\_mail at [compliance\\_officer@choksilab.com](mailto:compliance_officer@choksilab.com)

For and on behalf of the Board of Directors of  
**CHOKSI LABORATORIES LIMITED**

  
Vyangesh Choksi  
Whole Time Director  
DIN 00154926



Date: 13<sup>th</sup> August 2021  
Place: Indore